BASF, Izon Science, SPI Pharma
Date/Time: Sunday, July 22, 2018 - 8:30 AM to 9:30 AM
Open to all registered attendees on a complimentary basis, these forums offer in-depth coverage of technologies and services hosted by the presenting companies.
Meeting the Formulation Challenges of Bitter Tasting Drugs
Effective taste-masking of bitter APIs, especially for pediatric and geriatric drug products, is a very important challenge in the development of pharmaceutical dosage forms. This presentation will provide case-studies as examples of liquid dosage taste-masking using Kolliphor® RH40 and Kolliphor P188/407. In the case of taste-masking for solid oral dosage forms, the utility of BASF’s coating polymer excipient; Kollicoat® SR30D will be described. Lastly, the functional benefits and application of Kollicoat® Smartseal, a novel excipient that has been designed specifically for taste-masking, will be highlighted.
Nigel Langley – Director Technical Service and Scientific Affairs, Pharma Solutions - North America
Jiantao Zhang – Technical Service Manager, Pharma Solutions - North America
Single Particle Zeta Potential Characterization of Biological Nanoparticles using Tunable Resistive Pulse Sensing (TRPS)
Development, performance, and regulatory authorization of nanotechnology-based therapeutics are critically dependent on their physiological behaviors which in-turn relies on accurate, high-resolution nanoparticle characterization. Currently, several particle characterization techniques (such as TRPS, DLS/PALS, TEM, AFM, NTA, flow cytometry, etc.) exist, of which only Tunable Resistive Pulse Sensing (TRPS) provides simultaneous in-suspension information about particle size and zeta potential on particle-by-particle basis. The high resolution single particle size and zeta potential characterization provides a better understanding of variations among formulations enabling the analysis of a wide spectrum of nanoparticles and their mixtures. Thus, impacting nanomedicine development and their regulatory approval.
Anoop K. Pal - Chief Scientist - Americas Region
Dimitri Aubert - Global Sales Director
Designing Patient Friendly Dosage Forms to Target the Unique Therapeutic Needs of the ever-increasing Geriatric – “Silver Tsunami” - Patient Population
Presented by: Don Barbieri, Technical Development Manager – North America, SPI Pharma
As noted by Peter Scholes in a recent Pharmaceutical Technology Volume 2018 Supplement, “the so-called “silver tsunami” is poised to become one of the most meaningful social transformations of the 21st century.” *
With this concept in mind, SPI Pharma’s Technology Forum presentation is intended to initiate active discussion on developing dosage forms that are designed to meet the specialized needs of geriatric patient populations with a focus on improving patient therapeutic outcomes. If patients take their medications as prescribed, compliance increases with an associated increase in therapeutic success. Positive therapeutic outcomes can be accomplished through different approaches. One such approach is to develop Patient Friendly Dosage Forms. These products have good palatability, are convenient and easy for people to take, and improve the experience of taking and/or administering medication especially for those patients with dysphagia or other swallowing problems.
Patient Friendly Dosage Forms include, Orally Disintegrating Tablets (ODTs), soft gelatin capsules, Orally Dispersible Powders (ODP), chewable/meltable tablets, among others, and
offer scientists the opportunity to creatively develop extended and/or immediate release products in a wide range of size, shapes and flavors.
Such creativity will allow formulators to proactively address the specific dosing needs of the pending “silver tsunami” wave and the ever-increasing needs of diverse patient populations.
* Removing the Bitter Taste from Drug Development by Peter Scholes, Pharmaceutical Technology Volume 2018 Supplement, Issue 2, pg s6-s10